1.2Bridged carbocycle at R1
The substituent attaches to the scaffold through a carbon–carbon bond at one bridgehead. Three methylene bridges connect the bridgeheads and hold the five-carbon framework in a rigid shape.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The substituent attaches to the scaffold through a carbon–carbon bond at one bridgehead. Three methylene bridges connect the bridgeheads and hold the five-carbon framework in a rigid shape.
An ether oxygen connects the scaffold to a carbon bearing three fluorine atoms. The oxygen places the fluorinated carbon one additional bond from the scaffold and gives the attachment a bent geometry.
One alkyne carbon bonds directly to the scaffold, and the terminal carbon bears hydrogen. The triple bond holds the two-carbon substituent in a linear geometry.
A methylene group connects the scaffold to a carbon bearing three methyl groups. The methyl groups provide bulk around that carbon, and rotation about the methylene bonds changes their orientation relative to the scaffold.
A carbon–carbon double bond connects the two linker carbons, with one attachment group on each carbon. The E configuration holds the attachment groups on opposite sides of the double bond.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Replace the carboxamide connection with a 3,5-disubstituted 1,2,4-oxadiazole, with the pyridine fragment at C5 and the fragment corresponding to the amide nitrogen substituent at C3. Convert the nitrile of the C3 fragment to an amidoxime and acylate it with an activated pyridine carboxylic acid derivative. Cyclodehydrate the acylated amidoxime to close the heteroaromatic ring. The resulting connection is conformationally constrained and has no amide N–H hydrogen-bond donor.
Combine the pyridine carboxamide with hydroxypropyl beta-cyclodextrin in an aqueous formulation. Hold the compound loading and temperature constant while increasing the cyclodextrin concentration across a series of buffered samples. After equilibration, filter the samples and measure the dissolved compound by liquid chromatography. Select a cyclodextrin concentration from the measured solubility profile and check for precipitation after dilution into the intended medium.
R4 is a phenyl group attached through carbon 1, and p is 2. Fluorine at carbon 3 and methoxy at carbon 4 form the two R5 substituents.
R5 is an oxetan-3-yl group bonded to R4 through the carbon opposite the ring oxygen. The four-membered ring contains one oxygen and three carbons, and the oxygen acts as a hydrogen-bond acceptor.
The middle methylene in a three-carbon linker is replaced by oxygen to give —CH2—O—CH2—. Both ends attach through methylene carbons, and the internal oxygen acts as a hydrogen-bond acceptor.
R is a 2-hydroxyethyl group, —CH2CH2OH, attached through carbon 1. The terminal hydroxyl acts as both a hydrogen-bond donor and an acceptor.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
or a pharmaceutically acceptable salt thereof, wherein: Ring A is selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur optionally fused to a 5-6 membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygeA · US 2019/0233411 A1 · ¶
each Rx is independently an optionally substituted group selected from: C1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic partially unsaturated or aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatomsB · US 2022/0169612 A1 · ¶ 29
Suitable monovalent substituents on a substitutable carbon atom of an “optionally substituted” group are independently halogen; —(CH2)0-4R∘; —(CH2)0-4OR∘; —O(CH2)0-4R∘, —O—(CH2)0-4C(O)OR∘; —(CH2)0-4CH(OR∘)2; —(CH2)0-4SR∘; —(CH2)0-4Ph, which may be substituted with R∘; —(CH2)0-4O(CH2)0-1Ph which may be substituted with R∘; —CH═CHPh, which may be substituted with R∘; —(CH2)0-4O(CH2)0-1-pyridyl which may be substituted with R∘; —NO2; —CN; —N3; —(CH2)0-4N(R∘)2; —(CH2)0-4N(R∘)C(O)A · US 2019/0233411 A1 · ¶ 32
A compound according to Formula (I′): or a pharmaceutically acceptable salt thereof, wherein: A′, B′, and X′ are each independently nitrogen or carbon; each R1′ is independently halogen, —R′, —CN, —NO2, —SF5, —ORx, —NRx2, —NHRx, —SO2R′, —C(O)R′, —C(O)NR′2; each R′ is independently hydrogen or an optionally substituted group selected from: C1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic partiallyB · US 2022/0169612 A1 · claim 1
R3 is hydrogen, halogen, —CN, —OR′, —N(R′)2, or an optionally substituted group selected from C1-3 aliphatic, phenyl, or a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;A · US 2019/0233411 A1 · ¶
R2′, R3′, and R4′ are each independently halogen, —R′, —CN, —NO2, —OR′, —NR′2, or R2′ and R3′ together with the carbon form an optionally substituted 3-7 membered saturated carbocyclic ring; an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an optionally substituted 3-7 membered saturated or a partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independentlyB · US 2022/0169612 A1 · claim 1
In some embodiments R is an optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments R is an optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.A · US 2019/0233411 A1 · ¶ 80
Aryl groups may be substituted or unsubstituted. Representative substituted aryl groups may be mono-substituted or substituted more than once, such as, but not limited to, mono-, di-, or tri-substituted.B · US 2022/0169612 A1 · ¶ 101
Suitable monovalent substituents on a substitutable carbon atom of an “optionally substituted” group are independently halogen; —(CH2)0-4Ro; —(CH2)0-4ORo; —O(CH2)0-4Ro, —O—(CH2)0-4C(O)ORo; —(CH2)0-4CH(ORo)2; —(CH2)0-4SRo; —(CH2)0-4Ph, which may be substituted with Ro; —(CH2)0-4O(CH2)0-1Ph which may be substituted with Ro; —CH═CHPh, which may be substituted with Ro; —(CH2)0-4O(CH2)0-1-pyridyl which may be substituted with Ro; —NO2; —CN; —N3; —(CH2)0-4N(Ro)2; —(CH2)0-4N(Ro)C(O)B · US 2022/0169612 A1 · ¶ 107
An “alkylene chain” is a polymethylene group, i.e., —(CH2)n—, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent.A · US 2019/0233411 A1 · ¶ 22
L′ is optionally substituted C1-5 alkylene;B · US 2022/0169612 A1 · claim 1
Y1′, Y2′, Y3′, and Y4′ are each independently a covalent bond, a carbon, an oxygen, or a nitrogen, optionally substituted with hydrogen, an optionally substituted C1-6 alkyl, or an optionally substituted 3-7 membered saturated carbocyclic ring;B · US 2022/0169612 A1 · claim 1
In some embodiments R is hydrogen. In some embodiments R is an optionally substituted C1-6 aliphatic group.A · US 2019/0233411 A1 · ¶ 80
each R′ is independently hydrogen or an optionally substituted group selected from: C1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic partially unsaturated or aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4B · US 2022/0169612 A1 · ¶ 28
An empty cell means only that no passage was reproduced there.
For these reasons, there is a need for the development of potent and selective inhibitors of GCN2 for the treatment of cancer, either as single agents or in combination, for example with anti-CTLA4 and anti-PD1/PD-L1 checkpoint blocking antibodies.A · US 2019/0233411 A1 · ¶ 7
It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are effective as inhibitors of GCN2 kinase.A · US 2019/0233411 A1 · ¶ 8
The present disclosure is based at least in part on the identification of compounds that modulate adrenergic receptor and methods of using the same to treat diseases associated with an adrenergic receptor.B · US 2022/0169612 A1 · ¶ 7
Disclosed herein is a compound according to Formula (I) or an optically pure stereoisomer, pharmaceutically acceptable salt, solvate, or prodrug thereofB · US 2022/0169612 A1 · ¶ 7
patent.fyi, US 2026/0356833 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356833/, SHA-256 88b46ec9ae7f6f1d7396020c5497b86767059424a2fe45f02e35256f85976720